Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

In the gut mucosa of IgAN patients, expanded IgA + plasma cells highly express BCMA, supported by APRIL signals, leading to excess pathogenic IgA and kidney injury. Therapeutic depletion of these BCMA ...

SAN DIEGO – A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to ...

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics TM in oncology, today ...

B-cell maturation antigen (BCMA) immunohistochemistry (IHC) staining in multiple myeloma (MM) patients with prior use of BCMA-based therapies. This is an ASCO Meeting Abstract from the 2025 ASCO ...

CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, ...

Activity and toxicity of human mesenchymal stem cells derived from anti-PD1-integrated iPSCs. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...

In a clinical trial of 7 patients, anti-BCMA only CAR-T cell treated patients with refractory lupus nephritis safely and effectively. Anti-B cell maturation antigen (BCMA)-targeting chimeric antigen ...

BCMA-directed CAR T-cell therapy may be effective against high-risk smoldering multiple myeloma by American Association for Cancer Research edited by Gaby Clark, reviewed by Andrew Zinin Editors' ...

Detailed price information for Caribou Biosciences Inc (CRBU-Q) from The Globe and Mail including charting and trades.